Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2010

01.01.2010 | Original Article

Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells

verfasst von: Gangjun Du, Haihong Lin, Mei Wang, Shuo Zhang, Xianchuang Wu, Linlin Lu, Liyan Ji, Lijuan Yu

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The anthracycline antibiotic doxorubicin (DOX) has been used successfully for treating various types of cancers. However, the therapeutic efficacy of DOX was greatly restricted by its cumulative dose-related cardiotoxicity and common side effects such as bone marrow and immune suppression. Quercetin had better cardioprotective and hepatoprotective activities. The present study was to observe whether quercetin could improve therapeutic index of DOX and explore its mechanisms.

Methods

Effects of quercetin on doxorubicin (DOX)-induced cytotoxicity were investigated in 4T1 cells and murine spleen cells by methylthiazoletetrazolium assay, flow cytometry and single cell gel electrophoresis. Influences of quercetin on therapeutic efficacy and systemic toxicity of DOX were evaluated in BALB/c mice with 4T1 breast cancer. Hypoxia-inducible factor-1 alpha (HIF-1α) in tumor and normal cells was examined to explore mechanisms of quercetin by Western blot and enzyme-linked immunosorbent assay.

Results

In vitro, quercetin at dose less than 100 μM had only slight effects on cell viability and DOX-induced cytotoxicity in 4T1 cells under normoxia, but it could reverse 4T1 cell resistance to DOX under hypoxia and protect spleen cells against DOX-induced cytotoxicity. In vivo, quercetin suppressed tumor growth and prolonged survival in BALB/c mice bearing 4T1 breast cancer. Importantly, quercetin enhanced therapeutic efficacy of DOX and simultaneously reduced DOX-induced toxic side effects. Further study showed that quercetin suppressed intratumoral HIF-1α in a hypoxia-dependent way but increased its accumulation in normal cells. HIF-1α siRNA abolished effects of quercetin on both tumor and normal cells.

Conclusions

These results suggested that quercetin could improve therapeutic index of DOX by its opposing effects on HIF-1α in tumor and normal cells, and was a promising candidate as anticancer agents.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96CrossRefPubMed
2.
Zurück zum Zitat Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22PubMed Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22PubMed
3.
Zurück zum Zitat Morse R, Rodgers J, Verrill M, Kendell K (2003) Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review. Eur J Cancer 39:2288–2297CrossRefPubMed Morse R, Rodgers J, Verrill M, Kendell K (2003) Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review. Eur J Cancer 39:2288–2297CrossRefPubMed
4.
Zurück zum Zitat Gianni L (2009) Anthracyclines and early breast cancer: the end of an era? J Clin Oncol 27:1155–1157CrossRefPubMed Gianni L (2009) Anthracyclines and early breast cancer: the end of an era? J Clin Oncol 27:1155–1157CrossRefPubMed
5.
Zurück zum Zitat Gianni L, Salvatorelli E, Minotti G (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7(2):67–71CrossRefPubMed Gianni L, Salvatorelli E, Minotti G (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7(2):67–71CrossRefPubMed
6.
Zurück zum Zitat Benavente-García O, Castillo J, Alcaraz M, Vicente V, Del Río JA, Ortuño A (2007) Beneficial action of citrus flavonoids on multiple cancer-related biological pathways. Curr Cancer Drug Targets 7:795–809CrossRefPubMed Benavente-García O, Castillo J, Alcaraz M, Vicente V, Del Río JA, Ortuño A (2007) Beneficial action of citrus flavonoids on multiple cancer-related biological pathways. Curr Cancer Drug Targets 7:795–809CrossRefPubMed
7.
Zurück zum Zitat Formica JV, Regelson W (1995) Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 33:1061–1080CrossRefPubMed Formica JV, Regelson W (1995) Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 33:1061–1080CrossRefPubMed
8.
Zurück zum Zitat Hirpara KV, Aggarwal P, Mukherjee AJ, Joshi N, Burman AC (2009) Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer Agents Med Chem 9:138–161PubMed Hirpara KV, Aggarwal P, Mukherjee AJ, Joshi N, Burman AC (2009) Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer Agents Med Chem 9:138–161PubMed
9.
Zurück zum Zitat Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW, Kerr DJ (2001) Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann Oncol 12:245–248CrossRefPubMed Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW, Kerr DJ (2001) Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann Oncol 12:245–248CrossRefPubMed
10.
Zurück zum Zitat Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM, Castanas E (2000) Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem 78:429–441CrossRefPubMed Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM, Castanas E (2000) Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem 78:429–441CrossRefPubMed
11.
Zurück zum Zitat Conklin CM, Bechberger JF, MacFabe D, Guthrie N, Kurowska EM, Naus CC (2007) Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells. Carcinogenesis 28:93–100CrossRefPubMed Conklin CM, Bechberger JF, MacFabe D, Guthrie N, Kurowska EM, Naus CC (2007) Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells. Carcinogenesis 28:93–100CrossRefPubMed
12.
Zurück zum Zitat Hakimuddin F, Paliyath G, Meckling K (2004) Selective cytotoxicity of a red grape wine flavonoid fraction against MCF-7 cells. Breast Cancer Res Treat 85:65–79CrossRefPubMed Hakimuddin F, Paliyath G, Meckling K (2004) Selective cytotoxicity of a red grape wine flavonoid fraction against MCF-7 cells. Breast Cancer Res Treat 85:65–79CrossRefPubMed
13.
Zurück zum Zitat Verma N, Behera BC, Makhija U (2008) Antioxidant and hepatoprotective activity of a lichen Usnea ghattensis in vitro. Appl Biochem Biotechnol 151:167–181CrossRefPubMed Verma N, Behera BC, Makhija U (2008) Antioxidant and hepatoprotective activity of a lichen Usnea ghattensis in vitro. Appl Biochem Biotechnol 151:167–181CrossRefPubMed
14.
Zurück zum Zitat Mojzisová G, Mirossay L, Kucerová D, Kyselovic J, Mirossay A, Mojzis J (2006) Protective effect of selected flavonoids on in vitro daunorubicin-induced cardiotoxicity. Phytother Res 20:110–114CrossRefPubMed Mojzisová G, Mirossay L, Kucerová D, Kyselovic J, Mirossay A, Mojzis J (2006) Protective effect of selected flavonoids on in vitro daunorubicin-induced cardiotoxicity. Phytother Res 20:110–114CrossRefPubMed
15.
Zurück zum Zitat Duthie SJ, Collins AR, Duthie GG, Dobson VL (1997) Quercetin and myricetin protect against hydrogen peroxide-induced DNA damage (strand breaks and oxidised pyrimidines) in human lymphocytes. Mutat Res 393:223–231PubMed Duthie SJ, Collins AR, Duthie GG, Dobson VL (1997) Quercetin and myricetin protect against hydrogen peroxide-induced DNA damage (strand breaks and oxidised pyrimidines) in human lymphocytes. Mutat Res 393:223–231PubMed
16.
Zurück zum Zitat Granado-Serrano AB, Martín MA, Bravo L, Goya L, Ramos S (2006) Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr 136:2715–2721PubMed Granado-Serrano AB, Martín MA, Bravo L, Goya L, Ramos S (2006) Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr 136:2715–2721PubMed
17.
Zurück zum Zitat Tang N, Du GJ, Wang N, Liu CC, Hang HY, Liang W (2007) Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 99:1004–1015CrossRefPubMed Tang N, Du GJ, Wang N, Liu CC, Hang HY, Liang W (2007) Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 99:1004–1015CrossRefPubMed
18.
Zurück zum Zitat Collins AR (2004) The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26:249–261CrossRefPubMed Collins AR (2004) The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26:249–261CrossRefPubMed
19.
Zurück zum Zitat Choi HJ, Eun JS, Kim BG, Kim SY, Jeon H, Soh Y (2006) Vitexin, an HIF-1α inhibitor, has anti-metastatic potential in PC12 cells. Mol Cells 22:291–299PubMed Choi HJ, Eun JS, Kim BG, Kim SY, Jeon H, Soh Y (2006) Vitexin, an HIF-1α inhibitor, has anti-metastatic potential in PC12 cells. Mol Cells 22:291–299PubMed
20.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
21.
Zurück zum Zitat Lee DH, Lee YJ (2008) Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 105:546–553CrossRefPubMed Lee DH, Lee YJ (2008) Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 105:546–553CrossRefPubMed
22.
Zurück zum Zitat Jeon H, Kim H, Choi D, Kim D, Park SY, Kim YJ, Kim YM, Jung Y (2007) Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF prolyl hydroxylase. Mol Pharmacol 71:1676–1684CrossRefPubMed Jeon H, Kim H, Choi D, Kim D, Park SY, Kim YJ, Kim YM, Jung Y (2007) Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF prolyl hydroxylase. Mol Pharmacol 71:1676–1684CrossRefPubMed
23.
Zurück zum Zitat Triantafyllou A, Liakos P, Tsakalof A, Chachami G, Paraskeva E, Molyvdas PA, Georgatsou E, Simos G, Bonanou S (2007) The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 41:342–356CrossRefPubMed Triantafyllou A, Liakos P, Tsakalof A, Chachami G, Paraskeva E, Molyvdas PA, Georgatsou E, Simos G, Bonanou S (2007) The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 41:342–356CrossRefPubMed
24.
Zurück zum Zitat Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751PubMed Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751PubMed
25.
Zurück zum Zitat Ruiz MJ, Fernández M, Picó Y, Mañes J, Asensi M, Carda C, Asensio G, Estrela JM (2009) Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J Agric Food Chem 57:3180–3186CrossRefPubMed Ruiz MJ, Fernández M, Picó Y, Mañes J, Asensi M, Carda C, Asensio G, Estrela JM (2009) Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J Agric Food Chem 57:3180–3186CrossRefPubMed
26.
Zurück zum Zitat Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45:2179–2205CrossRefPubMed Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45:2179–2205CrossRefPubMed
27.
Zurück zum Zitat Utesch D, Feige K, Dasenbrock J, Broschard TH, Harwood M, Danielewska-Nikiel B, Lines TC (2008) Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res 654:38–44PubMed Utesch D, Feige K, Dasenbrock J, Broschard TH, Harwood M, Danielewska-Nikiel B, Lines TC (2008) Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res 654:38–44PubMed
28.
Zurück zum Zitat Scambia G, Ranelletti FO, Panici PB, DeVincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C, Cianfriglia M, Mancuso S (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34:459–464CrossRefPubMed Scambia G, Ranelletti FO, Panici PB, DeVincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C, Cianfriglia M, Mancuso S (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34:459–464CrossRefPubMed
29.
Zurück zum Zitat Boots AW, Li H, Schins RP, Duffin R, Heemskerk JW, Bast A, Haenen GR (2007) The quercetin paradox. Toxicol Appl Pharmacol 222:89–96CrossRefPubMed Boots AW, Li H, Schins RP, Duffin R, Heemskerk JW, Bast A, Haenen GR (2007) The quercetin paradox. Toxicol Appl Pharmacol 222:89–96CrossRefPubMed
30.
Zurück zum Zitat Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, Mueller MJ (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138:1615–1621PubMed Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, Mueller MJ (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138:1615–1621PubMed
Metadaten
Titel
Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells
verfasst von
Gangjun Du
Haihong Lin
Mei Wang
Shuo Zhang
Xianchuang Wu
Linlin Lu
Liyan Ji
Lijuan Yu
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2010
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-1032-7

Weitere Artikel der Ausgabe 2/2010

Cancer Chemotherapy and Pharmacology 2/2010 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.